Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Open Access
- 3 May 2023
- journal article
- letter
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specifiedExperimental Hematology & Oncology, 2021
- Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemiaBiomarker Research, 2021
- Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemiaAmerican Journal of Hematology, 2021
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemiaBlood Advances, 2019